Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 401–500 of 930
Yan, S., Liu, L., Zhang, X., Wei, L., Jiang, W., Gao, X., Yang, A., Liu, X., Chen, W., Chen, Y., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03342-y · Cited by 16
“With the advent of immunotherapy, the synergistic effect of chemoimmunotherapy was hypothesized and a neoadjuvant setting might reveal improved efficacy in reducing disease progression or metastasis [17–19].”
Huang, S., Huang, Y., Li, C., Liang, Y., Huang, M., Luo, R., & Liang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332213 · Cited by 16
Wang, J., Tong, T., Zhang, G., Jin, C., Guo, H., Liu, X., Zhang, Z., Li, J., & Zhao, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339757 · Cited by 16
Chang, J. H., Remulla, D. B., Wehrle, C. J., Woo, K. P., Dahdaleh, F. S., Joyce, D., & Naffouje, S. A. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15478-4 · Cited by 16
“18,19 This has been demonstrated in studies of multiple different carcinomas.”
BackgroundImmune checkpoint inhibition in early-stage non-small cell lung cancer
Cuppens, K., Pont, B. D., Knegjens, J., Maes, B., & Baas, P. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107855 · Cited by 18
Hepatocellular carcinoma systemic treatment update: From early to advanced stage
Teng, W., Wu, T.-C., & Lin, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100815 · Cited by 17
“Besides, data from a landmark study [29] using an orthotopic model of breast cancer showed that delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumor activity while also decreasing toxicity.”
Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes
Rodríguez‐Vida, A., Perez‐Gracia, J. L., & Joaquim Bellmunt, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3108 · Cited by 16
Gentzler, R. D., Riley, D., & Martin, L. W. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00969-w · Cited by 16
Adjuvant therapy of operable nonsmall cell lung cancer: an update
Mitsudomi, T., & Soh, J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000702 · Cited by 17
“preoperative therapy is better in a mouse model of breast cancer, and it was shown that the preoperative immunotherapy is better than immunotherapy after primary tumor resection [30].”
BackgroundZobel, M. J., Zamora, A. K., Wu, H., Sun, J., Lascano, D., Malvar, J., Wang, L. L., Sheard, M. A., Seeger, R. C., & Kim, E. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001560 · Cited by 16
Surgery for advanced-stage non-small cell lung cancer: lobectomy or sub-lobar resection?
Hao, Z., Liang, H., Zhang, Y., Wei, W., Lan, Y., Qiu, S., Lin, G., Wang, R., Liu, Y., Chen, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-39 · Cited by 16
Self-citationAnand, A. C., & Acharya, S. K. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.04.003 · Cited by 16
Repurposing Radiation Therapy for Immuno-oncology
Tang, J., Małachowska, B., Wu, X., & Guha, C. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.08.015 · Cited by 19
Short-course neoadjuvant in situ vaccination for murine melanoma
Aiken, T. J., Komjathy, D., Rodriguez, M., Stuckwisch, A. M., Feils, A. S., Subbotin, V. M., Birstler, J., Gillies, S. D., Rakhmilevich, A. L., Erbe, A. K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003586 · Cited by 16
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
NIKE Group, Gallo, M., Guarnotta, V., de Cicco, F., Rubino, M., Faggiano, A., & Colao, A. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02839-w · Cited by 16
Song, Y., Straker, R. J., Xu, X., Elder, D. E., Gimotty, P. A., Huang, A. C. C., Mitchell, T. C., Amaravadi, R. K., Schuchter, L. M., & Karakousis, G. C. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08174-1 · Cited by 16
“Preclinical studies suggest that neoadjuvant immunotherapy may be more efficacious than adjuvant therapy; in a murine model, improved survival was seen when T regulatory cells were depleted in the neoadjuvant setting.(11) However, few clinical studies have directly compared patient outcomes between neoadjuvant versus…”
BackgroundAdvances in Immunotherapy for Adult Glioblastoma
Chokshi, C., Brakel, B. A., Tatari, N., Savage, N. J., Salim, S. K., Venugopal, C., & Singh, S. K. (2021) · Cancers · doi:10.3390/cancers13143400 · Cited by 18
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?
Bilušić, M. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2069097 · Cited by 16
Hughes, E., Lauder, S. N., Smart, K., Bloom, A., Scott, J., Jones, E., Somerville, M., Browne, M., Blainey, A., Godkin, A., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02603-x · Cited by 15
Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
Pandey, P., Khan, F., Upadhyay, T. K., & Maqsood, R. (2023) · Molecules · doi:10.3390/molecules28020862 · Cited by 16
The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma
Bushara, O., Tidwell, J. C., Wester, J. R., & Miura, J. T. (2023) · Cancers · doi:10.3390/cancers15133344 · Cited by 16
“Further, neoadjuvant therapy not only may augment a more robust host immune response but also may serve to sustain this stronger response over the course of treatment [23].”
BackgroundChakrabarti, S., Grewal, U. S., Vora, K. B., Parikh, A. R., Almader‐Douglas, D., Mahipal, A., & Sonbol, M. B. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00182 · Cited by 16
“In a murine breast cancer model, Liu et al 17 demonstrated that administration of immunotherapy while the tumor is present results in superior tumor-speci fi c T-cell response leading to a better survival outcome and elimination of metastatic disease.”
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence
Vaidya, P., & Cohen, E. E. W. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0583 · Cited by 16
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024
Wang, K., Yang, J., Wang, B., Liu, Q., Wang, X., Yin, Y., Wang, H., Wang, S., Hao, C., Hao, X., et al. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-15 · Cited by 15
“…combination therapy with anti-programmed cell death protein 1 (PD-1) and anti-CD137 induces a stronger early expansion of tumor-specific cluster of differentiation 8 (CD8) + T cells than the same combination applied in the adjuvant setting and is directly associated with long-term survival (6).”
Wu, Y., Shang, J., Zhang, X., & Li, N. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02940-4 · Cited by 18
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 15
Molecular and therapeutic landscape of non-clear cell renal carcinoma
Nepali, P. R., Eraky, A., Okhawere, K. E., Dogra, N., Mehrazin, R., Badani, K. K., & Kyprianou, N. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01056-0 · Cited by 16
Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?
Arrieta, V. A., IWAMOTO, F. M., Lukas, R. V., Sachdev, S., Rabadán, R., & Sonabend, A. M. (2019) · Journal of neurosurgery · doi:10.3171/2019.9.jns192523 · Cited by 15
Boch, T., Frost, N., Sommer, L., Overbeck, T. R., Michaeli, C. T., Szuszies, C. J., Rieckmann, L.-M., Beumer, N., Imbusch, C. D., Winter, H., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.009 · Cited by 15
Su, P., Chen, J., Chu, C., Chen, Y., Chen, W.-L., Lin, K., Ho, C., Tsai, J., Yang, S., Chen, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07423-w · Cited by 16
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
Álvarez, M., Molina, C., Garasa, S., Ochoa, M. C., Rodriguez-Ruiz, M. E., Gomis, G., Cirella, A., Olivera, I., Glez‐Vaz, J., González-Gomariz, J., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2197370 · Cited by 15
“In these experimental settings, the original observations on neoadjuvant immunotherapy were made 6 .”
BackgroundMethodInfluentialNew Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
Gordan, J. D., Keenan, B. P., Lim, H. C., Yarchoan, M. M., & Kelley, R. K. (2023) · Drugs · doi:10.1007/s40265-023-01907-3 · Cited by 16
Immunotherapy for head and neck cancer: Fundamentals and therapeutic development
Okano, S. (2024) · Auris Nasus Larynx · doi:10.1016/j.anl.2024.05.001 · Cited by 15
Soares, A., Maia, M. C., Vidigal, F., & Monteiro, F. S. M. (2019) · Oncology · doi:10.1159/000502778 · Cited by 15
Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non–Small-Cell Lung Cancer
Kamigaichi, A., Tsutani, Y., Mimae, T., Miyata, Y., Shimada, Y., Ito, H., Nakayama, H., Ikeda, N., & Okada, M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.010 · Cited by 15
Olmos, M., Lutz, R., Büntemeyer, T.-O., Glajzer, J., Nobis, C.-P., Ries, J., Möst, T., Eckstein, M., Hecht, M., Gostian, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970823 · Cited by 15
“Frontiers in Immunology 10 adding 4 adjuvant doses had no benefit on overall survival and instead lead to an increase in immune related adverse events (15, 16).”
BackgroundMelanoma—the therapeutic considerations in the clinical practice
Adeleke, S. M., Okoli, S., Augustine, A., Galante, J. R., Agnihotri, A., Uccello, M., Ghose, A., Moschetta, M., & Boussios, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1432 · Cited by 14
Xie, S., Yang, L., Zhang, H., Tang, Z.-L., Lin, Z.-W., Chen, Y., Hong, Z.-N., Xu, R., Lin, W.-L., & Kang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332492 · Cited by 14
“Previous research has demonstrated that, in comparison to as adjuvants, immune checkpoint inhibitors (ICIs) offer distinct advantages as neoadjuvant therapy for eradicating distant metastases (28).”
ResultIntroducing Neoadjuvant Immunotherapy for Colorectal Cancer: Advancing the Frontier
Orhan, A., Justesen, T. F., Raskov, H., Qvortrup, C., & Gögenür, I. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006443 · Cited by 14
“67 This may partly explain the substantially lower objective response rates of ICIs in mCRC 71 compared with early-stage CRC. 6,72,73 Data support the use of ICIs in early-stage dMMR CRC, and results from large-scale studies are pending.”
Esagian, S. M., Karam, J. A., Msaouel, P., & Makrakis, D. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.08.002 · Cited by 14
Aronson, S. L., Thijssen, B., López‐Yurda, M., Koole, S. N., van der Leest, P., León‐Castillo, A., Harkes, R., Seignette, I. M., Sanders, J., Alkemade, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58440-y · Cited by 16
The untapped potential of radiation and immunotherapy for hormone receptor-positive breast cancer
Fenton, M., Yoneyama, M., Wennerberg, E., Lund, T., Tutt, A. N. J., Melcher, A. A., Demaria, S., & Somaiah, N. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00796-x · Cited by 14
“Pre-clinical evidence also suggests immunotherapy may also bemoreeffectiveintheneo-adjuvantversusadjuvantBCsetting 15 .”
Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
Roller, J., Veeramachaneni, N. K., & Zhang, J. (2022) · Cancers · doi:10.3390/cancers14030741 · Cited by 14
Preoperative immunotherapy for head and neck cancers: state of art
Egloff, A. M., & Uppaluri, R. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000826 · Cited by 14
Zhang, B., Li, X., Shu, W., Yang, Y., Zhu, H., & Shao, C. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.111067 · Cited by 14
Shao, L., & Lou, G. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1192 · Cited by 14
“After the clearance of the tumor, a stable pool of tumor-specific CD8 + T cells may remain (13).”
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
Sanber, K. S., Rosner, S., Forde, P. M., & Marrone, K. A. (2023) · BioDrugs · doi:10.1007/s40259-023-00614-5 · Cited by 14
“This is supported by findings from a pre-clinical study by Liu et al. that utilized a mouse model of metastatic triple-negative breast cancer (TNBC) [25].”
InfluentialImmunotherapy and Liver Transplantation
Tabrizian, P., Yu, A. T., Debnath, N., Myers, B., & Marron, T. U. (2023) · Surgical Clinics of North America · doi:10.1016/j.suc.2023.07.009 · Cited by 14
Deng, W., Chang, X., Dong, X., Zhao, Y., Yang, D., Jiang, L., Shi, A., Yu, H., Yu, R., Xiao, Z., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110955 · Cited by 16
Appleman, L. J., & Maranchie, J. K. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.06.005 · Cited by 15
Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination
Pol, J. G., Bridle, B. W., & Lichty, B. D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9794-7_12 · Cited by 17
Current management of melanoma patients with nodal metastases
Han, D., van Akkooi, A. C. J., Straker, R. J., Shannon, A. B., Karakousis, G. C., Wang, L., Kim, K. B., & Reintgen, D. S. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10099-7 · Cited by 14
Brown, L. C., & Loi, S. (2021) · The Breast · doi:10.1016/j.breast.2021.12.018 · Cited by 17
Hoeijmakers, L. L., Dimitriadis, P., Wijnen, S. C. M. A., Reijers, I. L. M., López‐Yurda, M., Menzies, A. M., Broeks, A., Cornelissen, S., Acosta, A. T., van der Wal, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04158-9 · Cited by 15
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song, F., Tarantino, P., Garrido-Castro, A. C., Lynce, F. C., Tolaney, S. M., & Schlam, I. M. (2024) · Current Oncology Reports · doi:10.1007/s11912-023-01487-1 · Cited by 14
“It has been reported that the primary tumor plays important roles in modulating immunologic changes, as its presence may enhance the expansion of tumor-specific T cells following the administration of immunotherapy [20].”
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Singla, N., Nirschl, T. R., Obradović, A., Shenderov, E., Lombardo, K. A., Liu, X., Pons, A., Zarif, J. C., Rowe, S. P., Trock, B. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51889-9 · Cited by 14
“We also corroborate prior preclinical findings from animal models of other malignancies demonstrating an increase in tumor-infiltrating CD8 + T cells following PD-1 blockade 25,26 .”
BackgroundResultInfluentialImmunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options
Chakravarty, D., Huang, L. T., Kahn, M., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.010 · Cited by 17
Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
Thai, A. A., Lim, A. M. L., Solomon, B., & Rischin, D. (2021) · Cancers · doi:10.3390/cancers13225645 · Cited by 15
Liu, L., Woo, Y., D’Apuzzo, M., Melstrom, L. G., Raoof, M., Liang, Y., Afkhami, M., Hamilton, S. R., & Chao, J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7023 · Cited by 13
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Conroy, M. R., Dennehy, C., & Forde, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107314 · Cited by 13
Preoperative therapy in melanoma: Evolving perspectives in clinical trials
Kakish, H. H., Xu, K. Y., Ahmed, F. A., Loftus, A. W., Elshami, M., Hoehn, R. S., Ammori, J. B., Mangla, A., & Rothermel, L. D. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104193 · Cited by 13
Induction treatment in patients with stage III non-small cell lung cancer
Palmero, R., Vilariño, N., Navarro-Martín, A., & Nadal, E. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-420 · Cited by 13
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Rwandamuriye, F. X., Weston, B. J., Johns, T. G., Lesterhuis, W. J., & Zemek, R. M. (2020) · Journal of Visualized Experiments · doi:10.3791/60882 · Cited by 13
Renner, A., Burotto, M., Valdés, J., Roman, J. C., & Walton‐Diaz, A. (2021) · Therapeutic Advances in Urology · doi:10.1177/17562872211029779 · Cited by 13
Hieken, T. J., Price, D. L., Piltin, M. A., Turner, H. J., & Block, M. S. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11112-9 · Cited by 13
Filling root canal systems with centered condensation: concepts, instruments, and techniques.
Buchanan, L. S. (2004) · PubMed · Cited by 13
Uppaluri, R., Campbell, K. M., Egloff, A. M., Zolkind, P., Skidmore, Z. L., Nussenbaum, B. A., Paniello, R. C., Rich, J. T., Jackson, R. S., Pipkorn, P. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4484 · Cited by 13
Liu, C.-C., Wolf, M. R., Ortego, R., Grencewicz, D. J., Sadler, T. M., & Eng, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-51361-8 · Cited by 13
“K) 27,28 .”
Guo, W., Qiao, T., Li, H., Zhao, Y., Qin, J., Zhang, C., & Shi, C. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217073 · Cited by 12
Neoadjuvant immunotherapy for non-small cell lung cancer: Opportunities and challenges
Hu, J., Zhang, J., Wan, S., & Zhang, P. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.11.003 · Cited by 13
The Role of Neoadjuvant Therapy in Melanoma
Kelly, Z. R., Gorantla, V. C., & Davar, D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00944-5 · Cited by 13
Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
Ren, L., Reyes, C. M., Frieß, H., & Demir, İ. E. (2020) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-020-01946-4 · Cited by 12
“administrated various combination immunotherapies in either neoadjuvant or adjuvant setting and discovered that regardless of the type of immunotherapy used, neoadjuvant approaches were superior to adjuvant treatments in primary breast tumors [53].”
BackgroundCross‐talk between tumors at anatomically distinct sites
Oliver, A. J., Darcy, P. K., Trapani, J. A., Kershaw, M. H., & Slaney, C. Y. (2020) · FEBS Journal · doi:10.1111/febs.15316 · Cited by 12
Botticelli, A., Mezi, S., Pomati, G., Sciattella, P., Cerbelli, B., Roberto, M., Mammone, G., Cirillo, A., Cassano, A., Dio, C. D., et al. (2020) · Vaccines · doi:10.3390/vaccines8020191 · Cited by 12
Mueller, K. L., Theoret, M. R., Lemery, S. J., Amiri‐Kordestani, L., Ariyan, C. E., Atkins, M. B., Berry, D. A., Blank, C. U., DeMichele, A. M., Forde, P. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3285 · Cited by 12
Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review
Gatteschi, L., Iannopollo, M., & Gonfiotti, A. (2021) · Life · doi:10.3390/life11101036 · Cited by 12
Nandi, D., & Sharma, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1477980 · Cited by 13
Zhang, Y., Yue, S., Zhang, B., Chen, X., & Zhang, W. (2025) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-24-175 · Cited by 11
“By introducing ICIs in the neoadjuvant setting, where the tumor burden is greater compared to the postoperative stage, there exists the theoretical potential to evoke a more substantial T-cell response (56).”
Melanoma neoadjuvant treatment: review and update of recent trials
Ferrari, M., Facchini, B. A., Ascierto, P. A., & Sparano, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2474182 · Cited by 12
“Preclinical studies support the idea that administering immunotherapy before surgery, with a higher tumor antigen load present, might improve the efficacy of the treatment [14].”
Cunha, M. T., Wallace, N. D., Porceddu, S. V., & Ferrarotto, R. (2025) · Cancer · doi:10.1002/cncr.35920 · Cited by 11
“40 In melanoma, neoadjuvant administration of PD1i has been found to be more effective than its adjuvant counter-part.”
Guan, S., Wang, Y., Liu, Q., Yan, M., Ren, K., Wang, J., Bi, N., & Zhao, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1591134 · Cited by 11
Ray-Coquard, I. L., Kaminsky, M., Ohkuma, R., de Montfort, A., Joly, F., Treilleux, I., Ghamry-Barrin, S., Bello-Roufai, D., Saintigny, P., Angelergues, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67646-z · Cited by 11
Fujimura, T., Kambayashi, Y., Sato, Y., Tanita, K., Amagai, R., Hashimoto, A., Hidaka, T., & Aiba, S. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00140 · Cited by 12
“Although there is still insufficient evidence for the efficacy of pre-operative treatment by nivolumab plus ipilimumab, these reports suggested that pre-operative treatment by nivolumab plus ipilimumab might induce a stronger and broader tumorspecific T cell response, as in a pre-clinical study (10).”
BackgroundCh’ng, S., Uyulmaz, S., Carlino, M. S., Pennington, T. E., Shannon, K. F., Rtshiladze, M. A., Stretch, J. R., Nieweg, O. E., Varey, A. H. R., Hsiao, E., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.037 · Cited by 11
Marjański, T., Dziedzic, R., Kowalczyk, A., & Rzyman, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212244 · Cited by 11
Hou, H., Wang, Y., Sun, D., Zhu, J., Jiang, M., Zhang, X., Zhou, N., Zhang, C., Li, T., & Zhang, X. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01324-5 · Cited by 11
Xu, Z., Zou, Z., Hao, X., Xing, P., & Li, J. (2023) · Cancer Innovation · doi:10.1002/cai2.49 · Cited by 11
“Pre-clinical model analysis has indicated an improved therapeutic efficacy of neoadjuvant compared with adjuvant immunotherapy to eradicate distant metastases, with increased tumor ‐ specific CD8 + T cells in peripheral blood and organs, predicting long ‐ term survival following surgery [12].”
BackgroundOspina, A. V., Nadal, S. B., de la Cruz, J. L. C.-C., González-Larriba, J. L., Vidueira, I. M., Sureda, B. M., Nadal, E., Hernándo, F., Álvarez, A., del Barco, E., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03382-y · Cited by 12
Günenç, D., Issa, W., Gerald, T., Zhou, Q., Zhang, S., Ibezue, C., Bhanvadia, R. R., Tachibana, I., Brugarolas, J., Hammers, H. J., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102177 · Cited by 11
From foes to friends: rethinking the role of lymph nodes in prostate cancer
Gupta, R., Das, C. K., Nair, S. S., Pedraza, A. M., Zahalka, A. H., Kyprianou, N., Bhardwaj, N., & Tewari, A. K. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00912-9 · Cited by 11
“In another study, a combination of anti-PD1 therapy and an agonistic CD137 antibody (a costimulatory receptor belonging to the tumour necrosis factor (TNF) receptor family 64 ) was administered in mouse breast cancer models in both the neoadjuvant and adjuvant settings 95 .”
Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530262 · Cited by 12
Hu, J., Yu, H., Sun, L., Yan, Y., Zhang, L., Jiang, G., & Zhang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650853 · Cited by 13
“prognosis in resectable solid tumor (30, 31), and neoadjuvant therapy may get more survival benefit than adjuvant therapy (32).”
BackgroundFeng, Y., Guo, K., Jin, H., Jiang, J., Wang, M., & Lin, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269067 · Cited by 12
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward
Harshman, L. C., Drake, C. G., Haas, N. B., Manola, J. B., Puligandla, M., Signoretti, S., Cella, D. F., Gupta, R. T., Bhatt, R. S., Allen, E. M. V., et al. (2017) · Kidney Cancer · doi:10.3233/kca-170010 · Cited by 11
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.06.08 · Cited by 12
A lyophilizable LNP vaccine enables STING-reinforced postoperational adjuvant immunotherapy
Yang, Y., Guo, J., Qi, J., Deng, W., Hu, J., Hasan, M. W., Deng, F., Zhou, Y. L., Song, Z., Deng, W., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03445-4 · Cited by 10
Key players in the breast cancer microenvironment: From fibroblasts to immune cells
Çakal, S., Urgancı, B. E., & Şimşek, S. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i7.107339 · Cited by 11
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy
Zhou, W., Huang, Z., Wu, Z., Tang, M., Zhu, L., Shi, W., Wang, Q., & Feng, L. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253017 · Cited by 10
“Preclinical studies have demonstrated that neoadjuvant ICB therapy enhances OS rates and antigen-specific T cell responses in a murine spontaneous metastatic breast tumor model compared with adjuvant therapy [47].”
Kadono, T., Yamamoto, S., & Kato, K. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac138 · Cited by 10
Cui, S., Wang, N., Liang, Y., Meng, Y. G., Shu, X., & Kong, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112903 · Cited by 10
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.